These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 27716253)
1. Nurse-administered intravitreal injections of anti-VEGF: study protocol for noninferiority randomized controlled trial of safety, cost and patient satisfaction. Austeng D; Morken TS; Bolme S; Follestad T; Halsteinli V BMC Ophthalmol; 2016 Oct; 16(1):169. PubMed ID: 27716253 [TBL] [Abstract][Full Text] [Related]
2. Nurse specialists for the administration of anti-vascular endothelial growth factor intravitreal injections. Samalia P; Garland D; Squirrell D N Z Med J; 2016 Jul; 129(1438):32-8. PubMed ID: 27447133 [TBL] [Abstract][Full Text] [Related]
4. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Ding X; Li J; Hu X; Yu S; Pan J; Tang S Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319 [TBL] [Abstract][Full Text] [Related]
5. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Brown DM; Wykoff CC; Wong TP; Mariani AF; Croft DE; Schuetzle KL; Retina; 2014 Sep; 34(9):1728-35. PubMed ID: 24914476 [TBL] [Abstract][Full Text] [Related]
6. Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice. Giocanti-Auregan A; Tadayoni R; Grenet T; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Quentel G; Cohen SY BMC Ophthalmol; 2016 Aug; 16():142. PubMed ID: 27507298 [TBL] [Abstract][Full Text] [Related]
7. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis. Zhou S; Gao J; Xu X Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion: twelve-month results of a prospective, randomized, multicenter trial. Kreutzer TC; Wolf A; Dirisamer M; Strauss RW; Foerster P; Feltgen N; Pielen A; Hattenbach LO; Kampik A; Priglinger SG Ophthalmologica; 2015; 233(1):8-17. PubMed ID: 25502833 [TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Boyer D; Heier J; Brown DM; Clark WL; Vitti R; Berliner AJ; Groetzbach G; Zeitz O; Sandbrink R; Zhu X; Beckmann K; Haller JA Ophthalmology; 2012 May; 119(5):1024-32. PubMed ID: 22440275 [TBL] [Abstract][Full Text] [Related]
10. Introduction of a nurse-led intravitreal injection service in ophthalmology. Gallagher MJ Br J Nurs; 2017 Jul; 26(14):800-803. PubMed ID: 28745964 [TBL] [Abstract][Full Text] [Related]
11. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G; Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488 [TBL] [Abstract][Full Text] [Related]
12. Retinal artery occlusion following intravitreal anti-VEGF therapy. von Hanno T; Kinge B; Fossen K Acta Ophthalmol; 2010 Mar; 88(2):263-6. PubMed ID: 19416108 [TBL] [Abstract][Full Text] [Related]
13. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699 [TBL] [Abstract][Full Text] [Related]
14. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977 [TBL] [Abstract][Full Text] [Related]
15. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Finger RP; Guymer RH; Gillies MC; Keeffe JE Ophthalmology; 2014 Jun; 121(6):1246-51. PubMed ID: 24518613 [TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes. Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625 [TBL] [Abstract][Full Text] [Related]
18. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program. Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion. Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055 [TBL] [Abstract][Full Text] [Related]
20. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months. Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ Retina; 2010; 30(7):1002-11. PubMed ID: 20616679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]